Aurinia Pharmaceuticals AUPH
NASDAQ AUPH
$16.15 +0.03 (+0.19%)
As of: Sep 4, 2026 · 3:11 PM EDT

Aurinia Pharmaceuticals (AUPH) Non Operating Interest Expenses (2023 - 2026)

Analysis

Aurinia Pharmaceuticals (AUPH) Non Operating Interest Expenses (2023 - 2026) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Non Operating Interest Expenses (Qtr)
1 Vertex Pharmaceuticals 138.58 Bn 130.73 Bn 2.84 Bn -
2 Regeneron Pharmaceuticals 85.33 Bn 77.33 Bn 3.93 Bn 11.00 Mn
3 Argenx Se 63.43 Bn 58.24 Bn 1.37 Bn -1.00 Mn
4 Moderna 57.84 Bn 52.70 Bn 52.00 Mn -
5 Revolution Medicines 44.01 Bn 44.01 Bn - 23.78 Mn
6 BeOne Medicines 39.93 Bn 34.83 Bn 1.53 Bn 39.74 Mn
7 Alnylam Pharmaceuticals 35.47 Bn 32.16 Bn 992.69 Mn 82.05 Mn
8 Royalty Pharma 28.39 Bn 27.56 Bn - 93.62 Mn
9 Insmed 27.48 Bn 26.32 Bn 358.27 Mn 20.27 Mn
10 Aurinia Pharmaceuticals 2.10 Bn 1.66 Bn 76.67 Mn 948,000.00
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 948,000.00
Mar 31, 2026 1.01 Mn
Dec 31, 2025 1.05 Mn
Sep 30, 2025 1.10 Mn
Jun 30, 2025 1.12 Mn
Mar 31, 2025 1.07 Mn
Dec 31, 2024 1.15 Mn
Sep 30, 2024 1.21 Mn
Jun 30, 2024 1.20 Mn
Mar 31, 2024 1.28 Mn
Dec 31, 2023 1.31 Mn
Sep 30, 2023 1.40 Mn
Jun 30, 2023 65,000.00